GSK announces significant post-Brexit UK investment
pharmafile | July 27, 2016 | News story | Manufacturing and Production, Research and Development | GSK, UK, brexit, investment
GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 million will be invested in manufacturing sites in Co. Durham, Hertfordshire and Scotland.
The vast majority of the products made at the Barnard Castle, Montrose and Ware facilities will be for export to global markets.
At Barnard Castle, £92 million will fund the construction of an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in their pipeline. It currently employs 1,100 people and supplies nearly half a million packs of products per day to 140 global markets.
The Scottish site in Montrose will benefit from a new £110 million state-of-the-art respiratory active ingredients manufacturing facility. The £74 million expansion at the Ware site will provide for further expansion of the company’s Ellipta respiratory inhalers.
The announcement is seen as a significant show of backing to life sciences in the UK after the Brexit vote, as uncertainty reigns over the country’s place within the research and development community as it cedes from the EU.
GSK chief executive, Sir Andrew Witty, says: “Today’s announcement reflects further investment to support out pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products. It is a testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here.”
Sean Murray
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
